Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
Source: ClinicalTrials.gov NCT01671605 ↗Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY In Vitro Lipoprotein Functions |
20.8; 26.5 | — |
Eligibility Criteria
Inclusion Criteria
Patients with moderate degree of CKD, or patients with advanced CKD or control subjects with intact kidney function
Male or female
All ethnic groups
≥ 18 years and have signed informed consent
Exclusion Criteria
Pregnancy and current smoking
BMI > 45
Rheumatoid arthritis and systemic lupus erythematosus
History of active or chronic hepatitis B, history of active or chronic hepatitis C, human immunodeficiency virus (HIV)
For moderate CKD subjects: nephrotic syndrome
For control subjects: nephrotic syndrome, patients with estimated GFR < 60 mL/min/1.73 m^2, or proteinuria
Data sourced from ClinicalTrials.gov (NCT01671605). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.